NeilCurtisDunavinMD

Hematology • San Francisco, CA

Physician

Join to view full profile

Dr. Dunavin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dunavin's full profile

Already have an account?

Office
400 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2421

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
Ohio State University HospitalResidency, Internal Medicine, 2009 - 2012
University of Kansas School of MedicineClass of 2009

Certifications & Licensure

CA State Medical License 2019 - 2025
MD State Medical License 2015 - 2022
KS State Medical License 2016 - 2020
OH State Medical License 2009 - 2017
DC State Medical License 2013 - 2014
American Board of Internal Medicine Hematology

Clinical Trials

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia Start of enrollment: 2012 Jun 06
Completed
Phase 1

Publications & Presentations

PubMed

A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.
Vanessa E Kennedy, Roberto Ruiz-Cordero, Diwash Jangam, Kwun Wah Wen, Neil Dunavin
Clinical Lymphoma, Myeloma & Leukemia. 2021-07-01
44 citations
WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1
Meizhang Li, Rupal Soder, Sunil Abhyankar, Haitham Abdelhakim, Mitchell W. Braun
Journal of Extracellular Vesicles. 2021-02-01
23 citations
A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Ver...
Rupal Soder, Buddhadeb Dawn, Mark L. Weiss, Neil Dunavin, Scott Weir
Stem Cell Reviews and Reports. 2020-10-01

Abstracts/Posters

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing
Neil Dunavin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Emerging Agents, Treatment Selection Criteria Key to Improving Outcomes in MyelofibrosisJanuary 20th, 2020
Dr. Dunavin on Treatment Considerations in MyelofibrosisJanuary 10th, 2020